AGC Inc.Download PDFPatent Trials and Appeals BoardJan 25, 20212020004744 (P.T.A.B. Jan. 25, 2021) Copy Citation UNITED STATES PATENT AND TRADEMARK OFFICE UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 15/370,763 12/06/2016 Jun ENDO 479348US99CONT 7740 22850 7590 01/25/2021 OBLON, MCCLELLAND, MAIER & NEUSTADT, L.L.P. 1940 DUKE STREET ALEXANDRIA, VA 22314 EXAMINER BOLDEN, ELIZABETH A ART UNIT PAPER NUMBER 1731 NOTIFICATION DATE DELIVERY MODE 01/25/2021 ELECTRONIC Please find below and/or attached an Office communication concerning this application or proceeding. The time period for reply, if any, is set in the attached communication. Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es): OBLONPAT@OBLON.COM iahmadi@oblon.com patentdocket@oblon.com PTOL-90A (Rev. 04/07) UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD Ex parte JUN ENDO, SHUSAKU AKIBA, KAZUTAKA ONO, and SHIGEKI SAWAMURA Appeal 2020-004744 Application 15/370,763 Technology Center 1700 Before BEVERLY A. FRANKLIN, KAREN M. HASTINGS, and JAMES C. HOUSEL, Administrative Patent Judges. HASTINGS, Administrative Patent Judge. DECISION ON APPEAL STATEMENT OF THE CASE Pursuant to 35 U.S.C. § 134(a), Appellant1 appeals from the Examiner’s decision to reject claims 2–12 and 14. See Final Act. 1. Claim 1 We use the term “Appellant” to refer to “applicant” as defined in 37 C.F.R. § 1.42. Appellant identifies the real party in interest as Asahi Glass Company, Limited. Appeal Br. 1. Appeal 2020-004744 Application 15/370,763 2 13 was cancelled.2 An oral hearing was conducted January 8, 2021. We have jurisdiction under 35 U.S.C. § 6(b). We AFFIRM. CLAIMED SUBJECT MATTER The claims are directed to a glass composition. Claim 2, reproduced below, is illustrative of the claimed subject matter: 2. A glass for chemical tempering, comprising, as represented by mole percentage based on the following oxides: from 66.6 to 70.0 % of SiO2: from 10.2 to 14 % of Al2O3; from 0 to 7% of MgO; from 0 to 1.0% SrO, from 0 to 1.0% BaO, from 0 to 0.5% CaO; from 0 to 4% of ZrO2; from 11 to 14.6% of Na2O: from 0 to 1.9% of K2O; and at least one component selected from the group consisting of B2O3, SrO and BaO; wherein a content of the B2O3 is at most 4.2%, and R’ calculated by the following formula by using contents of the respective components, is at least 0.74: R’=0.029xSiO2+0.021xAl2O3+0.0l6xMgO- 0.004xCaO+0.0l6xZrO2+0.029xNa2O+0xK2O+0.028xB2O3+ 0.012xSrO+0.026xBaO-2.002. 2 Claim 13 was cancelled and claim 2 was amended on September 6, 2019, after the Final Office Action mailed June 13, 2019, and the Examiner indicated this amendment was “OK TO ENTER” on October, 10, 2019. Appeal 2020-004744 Application 15/370,763 3 REFERENCES The prior art relied upon by the Examiner is: Name Reference Date Aitken US 2011/0017297 A1 Jan. 27, 2011 REJECTIONS Claims 2–12 and 14 are rejected under 35 U.S.C. § 112, first paragraph, as failing to comply with the written description requirement. Final Act. 5. Claims 2–12 and 14 are rejected under 35 U.S.C. § 103(a) as being unpatentable over Aitken. Final Act. 7. The Examiner withdrew the § 112 rejection for indefiniteness. Ans. 10. We will not address the Examiner’s objection to the Specification made by the Examiner (Final Act. 2–4) as this objection should be decided by the Director on petition, and is not appealable. See, e.g., MPEP §§ 706.01, 1201 (9th ed. Rev.08.2017 Jan. 2018). OPINION The 112 rejection for lack of written description For an applicant to comply with the 35 U.S.C. § 112, first paragraph, written description requirement, the applicant’s specification must “convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention.” Carnegie Mellon Univ. v. Hoffmann-La Roche Inc., 541 F.3d 1115, 1122 (Fed. Cir. 2008) Appeal 2020-004744 Application 15/370,763 4 (quoting Vas-Cath Inc. v. Mahurkar, 935 F.2d 1555, 1563–64 (Fed. Cir. 1991)). Claim 2 recites that the composition of claim 1 has 0 to 7% MgO. The Examiner states that the portion of the range from 0 to 3% is new matter as the Specification indicates that MgO is essential, and describes an amount of MgO no lower than 3% (Final Act. 5) While we appreciate the Examiner’s position that the Specification is confusing and appears to be somewhat inconsistent on this issue, there is no dispute that the Specification discloses numerous examples wherein the amount of MgO is 0 (less than 3%) (Spec., Tables 8-11, Examples 41, 42, 49–54, 56–65, and 74–78). The Examiner believes that these examples are not part of the disclosed invention, mainly because the Specification also states that “MgO is a component to improve the melting property, and is essential” (Spec. 14, l. 32; Ans. 26). Appellant’s position is that the Specification statement that MgO is essential is “regarding only one embodiment of glass of the present invention” (Appeal Br. 6) and that Examples 49-653 are examples of the present invention containing 0% MgO (id.). In light of the numerous examples described in the Specification containing 0% MgO, a preponderance of the evidence supports Appellant’s position that one of ordinary skill in the art would have appreciated that Appellant was in possession of glass compositions encompassing the recited range of 0 to 7% MgO (Reply Br. 2, 3; Appeal Br. 4–7). 3 Example 55 lists an amount of MgO content of 9.1; however, Examples 49–54 and 56–65 list 0 for the amount of MgO. Appeal 2020-004744 Application 15/370,763 5 The § 103 Rejection After considering the evidence presented in this Appeal and each of Appellant’s arguments, we are not persuaded that Appellant identifies reversible error. We review the appealed rejections for error based upon the issues identified by Appellant and in light of the arguments and evidence produced thereon. In re Jung, 637 F.3d 1356, 1365–66 (Fed. Cir. 2011) (explaining the Board’s long-held practice of requiring Appellant to identify the alleged error in the Examiner’s rejection). We sustain the Examiner’s rejections for the reasons expressed in the Final Office Action and the Answer. We add the following primarily for emphasis. Appellant does not dispute that Aitken discloses a glass composition with amounts of each component listed in Claim 2 that overlap those in Aitken. Appellant contends that Aitken does not address the problem addressed by the present invention of glass tempering, and relies upon the Declaration of Dr. Shusaku Akiba filed Sept. 28, 2018, as evidence of unexpected results (Appeal Br. 7–10; Reply Br. 3–4). These arguments are not persuasive of reversible error in the Examiner’s obviousness determination. As pointed out by the Examiner, “for chemical tempering” is merely an intended use of the recited composition of claim 2 (e.g., Ans. 28). Aitken is not limited to the example discussed in the Declaration and Appellant does not dispute that Aitken more broadly teaches all of the components of the glass composition recited in claim 2 in amounts that overlap the claimed amounts (as well as separately argued claim 6 that recites “at most 0.5%” of SrO (Appeal Br. 10; Ans. 32, (pointing out that Aitken discloses examples Appeal 2020-004744 Application 15/370,763 6 with zero SrO))). It is well established that when claimed ranges overlap or lie inside ranges disclosed by the prior art, a prima facie case of obviousness is established. In re Harris, 409 F.3d 1339, 1341 (Fed. Cir. 2005); In re Peterson, 315 F.3d 1325, 1330 (Fed. Cir. 2003). It is well settled that a reference is not limited to its examples or preferred embodiments. See, e.g., Merck & Co., Inc. v. Biocraft Labs., Inc., 874 F.2d 804, 807 (Fed. Cir. 1989). It is within the level of ordinary skill in the art to vary the amounts of the components such that the relationship R as defined in the claims would have been met/arrived at using no more than ordinary creativity. KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398, 418 (2007) (“[T]he [obviousness] analysis need not seek out precise teachings directed to the specific subject matter of the challenged claim, for a court can take account of the inferences and creative steps that a person of ordinary skill in the art would employ.”). With respect to the proffered evidence of unexpected results, Appellant has not provided the required side-by-side comparison of the claimed invention with the closest prior art which is commensurate in scope with the claims, and has not adequately explained why the results would have been unexpected by one of ordinary skill in the art. See In re Baxter Travenol Labs., 952 F.2d 388, 392 (Fed. Cir. 1991); In re Klosak, 455 F.2d 1077, 1080 (CCPA 1972). The evidence must show that the unexpected results extend throughout the claimed subject matter but do not extend into the prior art teachings that fall outside of the claimed subject matter, i.e., that the claimed ranges are critical for obtaining the unexpected result. See, e.g., In re Harris, 409 F.3d 1339, 1344 (Fed. Cir. 2005) (“Even assuming that the results were unexpected, Harris needed to show results covering the scope of the claimed range. Alternatively Harris needed to narrow the claims.”); In re Appeal 2020-004744 Application 15/370,763 7 Greenfield, 571 F.2d 1185, 1189 (CCPA 1978) (“Establishing that one (or a small number of) species gives unexpected results is inadequate proof, for ‘it is the view of this court that objective evidence of non-obviousness must be commensurate in scope with the claims which the evidence is offered to support.”’) (quoting In re Tiffin, 448 F.2d 791, 792 (CCPA 1971)); and In re Hill, 284 F.2d 955, 958–59 (CCPA 1960) (To establish unexpected results over a claimed range, an applicant should compare a sufficient number of tests both inside and outside the claimed range to show the criticality of the claimed range.). As pointed out by the Examiner, the proffered evidence has not been shown to be commensurate in scope with the claimed composition (Ans. 28). Indeed, Example 1 of the Declaration is not even encompassed by claim 2 since the amount of SrO (an amount listed as “2”) exceeds that required in claim 2 of “0 to 1.0% SrO”. Claim 2 also uses the open ended term “comprising” and thus may include other components not recited. Appellant has not met their burden to show that the results of one example (Example 2 of the Declaration) may be extrapolated throughout the breadth of the claim. We, therefore, discern no error in the Examiner’s determination that the applied prior art would have rendered obvious the glass composition of claim 2. Thus, Appellant has not persuasively argued that the facts and reasons relied on by the Examiner are insufficient to establish a prima facie case of obviousness. In light of these circumstances, the preponderance of the evidence supports the Examiner’s rejection. Accordingly, we sustain the rejection of the claims on appeal. Appeal 2020-004744 Application 15/370,763 8 CONCLUSION The Examiner’s § 112 rejection for lack or written description is reversed. The Examiner’s § 103 rejection is affirmed. DECISION SUMMARY Claim(s) Rejected 35 U.S.C. § Reference(s)/Basis Affirmed Reversed 2–12, 14 112 Lack of Written Description 2–12, 14 2–12, 14 103 Aitken 2–12, 14 Overall Outcome 2–12, 14 No time period for taking any subsequent action in connection with this appeal may be extended under 37 C.F.R. § 1.136(a)(1)(iv). AFFIRMED Copy with citationCopy as parenthetical citation